The overall goal of this study is to study circulating tumor DNA (ctDNA) in the blood to determine how cancer cells in patients react to treatment. DNA is short for deoxyribonucleic acid. DNA contains information that determines in part the traits, such as eye color, height, or disease risk, that are passed on from parent to child. This reaction will be measured by studying patient blood that will be collected before and during treatment until there is disease progression.
This study is for patients that have been diagnosed with diffuse large B-cell lymphoma (DLBCL) or Grade 3b follicular lymphoma that has never been treated. The investigational drug in this study is denintuzumab mafodotin. The purpose of this study is to find out what the side effects are and whether it is more or less effective when it is given together with other drugs that are a standard approved treatment for use in patients with lymphoma (DLBCL or FL3B). Participants can expect to be in the study for 4 years or until the study is closed or until they stop taking part.
This study is for subjects who have been diagnosed with a type of lymph gland disease called Hodgkin Lymphoma which has come back or has not gone away after treatment, including the best treatment known for these diseases. Researchers believe subjects will benefit from an allogeneic (from another human) stem cell transplant which has been offered as a form of treatment for this disease in many other patients. After transplant we will provide a type of medication that targets the CD30+ protein, a protein that is commonly expressed in Hodgkin Lymphoma. This medication is called Brentuximab Vedotin (or Brentuximab). Subjects will be offered treatment with lower doses of chemotherapy drugs, as compared to the higher doses of chemotherapy drugs historically used in transplants for other diseases. This is known as reduced intensity therapy.The main purpose of this study is to determine the safety and outcome of following reduced intensity conditioning and allogeneic stem cell transplantation in selected patients with Hodgkin Lymphoma (specifically CD30+ HL patients) with Brentuximab Vedotin. Subjects can expect to be in this study for 3 years.
This study is for patients that have been diagnosed with Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-Cell Lymphoma (DLBCL). The investigational drug in this study is Entospletinib (GS-9973) [referred to as ENTO]. The purpose of this study is to see if the study drug, ENTO can benefit subjects with Non-Hodgkin Lymphoma,can safely be combined with vincristine (VCR) and can have a beneficial effect in combination with VCR and VCR-based combination therapy (R-CHOP and DA-R-EPOCH). Participants can expect to be in this study for up to 5 years.
This phase II clinical trial is studying how well response-based therapy assessed by PET scan works in treating patients with bulky stage I and stage II Hodgkin lymphoma. PET scans will be obtained during the course of therapy. Researchers will evaluate the usefulness of this PET scan to determine whether radiation may be left out in the treatment of disease if the PET scan shows a response to chemotherapy alone. In addition, a small percentage of patients may have disease that is not adequately treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy. Researchers hope to identify this group of patients using early PET scans and will change to a chemotherapy treatment called BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
This clinical trial is being done to collect information about various long-term effects commonly seen in children who survive a stem cell transplant. In particular, information about renal (kidney), cardio-metabolic (heart disease and diabetes) and skeletal (bone) long-term effects will be collected for two years after transplant.